That's about $4.5m per quarter so during the latest quarter with $4.6m we should be break-even. Any growth going forward puts us cashflow positive?
If we end up FY25 with say $30m in revenue (translates to a quarterly average of $7.5m which is quite possible based on current growth rates and contract wins) less $18m expenses would leave us $12m cash flow positive. Surely that would value the company at well over $100m and makes Mynd's 15c highly opportunistic.
- Forums
- ASX - By Stock
- IDT
- Ann: Strong Q4 Pushes Full-Year Revenue Ahead of Guidance
Ann: Strong Q4 Pushes Full-Year Revenue Ahead of Guidance, page-13
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.43M |
Open | High | Low | Value | Volume |
11.5¢ | 12.0¢ | 11.5¢ | $7.429K | 64.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 328317 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 78950 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 328317 | 0.115 |
6 | 243601 | 0.110 |
4 | 457133 | 0.105 |
3 | 208000 | 0.100 |
1 | 30000 | 0.099 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 78950 | 4 |
0.125 | 250000 | 2 |
0.130 | 102341 | 1 |
0.135 | 60641 | 3 |
0.140 | 90000 | 3 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online